More troubles for LevFin as Elan postponed

© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

More troubles for LevFin as Elan postponed

Elan, the Irish biotechnology group, had pulled the sale of Elan Drug Technologies, its delivery unit, because buyers could not secure the debt they needed, bankers said this week. Bain Capital, Candover and TPG were all interested in EDT, which was expected to fetch about Eu1bn.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login
  • 4,000 annual insights
  • 700+ notes and long-form analyses
  • 4 capital markets databases
  • Daily newsletters across markets and asset classes
  • 2 weekly podcasts
Gift this article